PDI is a leading healthcare commercialization company providing superior go-to-market strategy and execution to established and emerging healthcare companies through its three core business units. The company's Sales Services business unit (CSO) is a leading provider of outsourced pharmaceutical, medical device and diagnostics sales teams. PDI's Product Commercialization Services, including Interpace Diagnostics and the ThyGenX NGS Test, provides full product commercialization and is working to develop and commercialize molecular diagnostic tests leveraging the latest technology and personalized medicine for better patient diagnosis and management. Its Marketing Services division is a pioneer in insight-driven digital c... More >>
|04/15/15||PDI, Inc. Subsidiary Interpace Diagnostics Sets New Precedent with Launch of ThyraMIR™, First and Only MicroRNA Gene Expression Classifier for Thyroid Nodule Identification|
|Unsurpassed Performance in Identifying Benign and Malignant Thyroid Nodules, with Negative Predictive Value of 94% and Positive Predictive Value of 74% in Combination with ThyGenX™(1)
PARSIPPANY, N.J., April 15, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today the launch of ThyraMIR™, the first and only microRNA (miRNA) gene expression classifier for identification of indeterminate benign and malignant thyroid nodules.
ThyraMIR, used in c... |
|03/09/15||PDI, Inc. Subsidiary Interpace Diagnostics Announces New Data Supporting Use of ThyraMIR™ - First and Only MicroRNA Gene Expression Classifier - with ThyGenX™ Thyroid Oncogene Panel to Improve Identification of Both Benign and Malignant Thyroid Nodules|
|Combined Platform Test Achieved High Negative Predictive Value (NPV) of 94% and Positive Predictive Value (PPV) of 74%
PARSIPPANY, N.J., March 9, 2015 /PRNewswire/ -- PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR™, the first and only microRNA expression classifier, and ThyGenX™ Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis. The study, prese... |
|03/05/15||PDI, Inc. to Present at The 27th Annual ROTH Conference|
|PARSIPPANY, N.J., March 5, 2015 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that Nancy Lurker, the company's chief executive officer and Graham Miao, the company's chief financial officer, are scheduled to present at the 27th Annual ROTH Conference at 3:00 pm PT on March 10, 2015 at the Ritz-Carlton Laguna Nigel in Dana Point, CA.
The live webcast may be accessed under the "Investor Relations" tab on the company's website at http://www.pdi-inc.com. The webcast will be arc... |
|03/03/15||PDI Reports Fourth Quarter and Full Year 2014 Financial Results|
|Commercial Services Win Several Recent Customer Assignments
Interpace Diagnostics Integration & Sales Force Expansion Completed
Company Provides 2015 Financial Outlook for Double-Digit Revenue Growth
Conference Call Today, March 3rd 2015 at 4:30 pm ET
PARSIPPANY, N.J., March 3, 2015 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today reported financial and operational results for the fourth quarter and fiscal year ended December 31, 2014.
Net revenue for the fourth quarter of 201... |